Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts

Komatsu,Yuko; Ibi,Miho; Chosa,Naoyuki; Kyakumoto,Seiko; Kamo,Masaharu; Shibata,Toshiyuki; Sugiyama,Yoshiki; Ishisaki,Akira

doi:10.3892/ijmm.2016.2582

Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts

Authors:
- Yuko Komatsu
- Miho Ibi
- Naoyuki Chosa
- Seiko Kyakumoto
- Masaharu Kamo
- Toshiyuki Shibata
- Yoshiki Sugiyama
- Akira Ishisaki
View Affiliations

Affiliations: Division of Cellular Biosignal Sciences, Department of Biochemistry, Iwate Medical University, Iwate 028‑3694, Japan, Department of Oral and Maxillofacial Surgery, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan, Division of Oral and Maxillofacial Surgery, Department of Reconstructive Oral and Maxillofacial Surgery, Iwate Medical University, Iwate 020-8505, Japan
Published online on: May 10, 2016 https://doi.org/10.3892/ijmm.2016.2582
Pages: 139-147
Copyright: © Komatsu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bisphosphonates (BPs) are analogues of pyrophosphate that are known to prevent bone resorption by inhibiting osteoclast activity. Nitrogen-containing BPs, such as zoledronic acid (ZA), are widely used in the treatment of osteoporosis and bone metastasis. However, despite having benefits, ZA has been reported to induce BP-related osteonecrosis of the jaw (BRONJ) in cancer patients. The molecular pathological mechanisms responsible for the development of BRONJ, including necrotic bone exposure after tooth extraction, remain to be elucidated. In this study, we examined the effects of ZA on the transforming growth factor-β (TGF‑β)-induced myofibroblast (MF) differentiation of human gingival fibroblasts (hGFs) and the migratory activity of hGFs, which are important for wound closure by fibrous tissue formation. The ZA maximum concentration in serum (Cmax) was found to be approximately 1.47 µM, which clinically, is found after the intravenous administration of 4 mg ZA, and ZA at this dose is considered appropriate for the treatment of cancer bone metastasis or bone diseases, such as Erdheim-Chester disease. At Cmax, ZA significantly suppressed i) the TGF‑β-induced promotion of cell viability, ii) the TGF‑β-induced expression of MF markers such as α-smooth muscle actin (α-SMA) and type I collagen, iii) the TGF‑β-induced migratory activity of hGFs and iv) the expression level of TGF‑β type I receptor on the surfaces of hGFs, as well as the TGF‑β-induced phosphorylation of Smad2/3. Thus, ZA suppresses TGF‑β-induced fibrous tissue formation by hGFs, possibly through the inhibition of Smad‑dependent signal transduction. Our findings partly elucidate the molecular mechanisms underlying BRONJ and may prove to be beneficial to the identification of drug targets for the treatment of this symptom at the molecular level.

View Figures

View References

1	Gong L, Altman RB and Klein TE: Bisphosphonates pathway. Pharmacogenet Genomics. 21:50–53. 2011. View Article : Google Scholar :
2	Boonyapakorn T, Schirmer I, Reichart PA, Sturm I and Massenkeil G: Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44:857–869. 2008. View Article : Google Scholar : PubMed/NCBI
3	Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M and Otto S: Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 44:568–585. 2015. View Article : Google Scholar : PubMed/NCBI
4	Manaka K, Makita N and Iiri T: Erdheim-Chester disease and pituitary involvement: a unique case and the literature. Endocr J. 61:185–194. 2014. View Article : Google Scholar
5	Rogers MJ, Crockett JC, Coxon FP and Mönkkönen J: Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 49:34–41. 2011. View Article : Google Scholar
6	Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, et al: Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 27:5356–5362. 2009. View Article : Google Scholar : PubMed/NCBI
7	Marx RE, Sawatari Y, Fortin M and Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 63:1567–1575. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE and Mehrotra B; American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 67(Suppl 5): 2–12. 2009.PubMed/NCBI
9	Hansen T, Kunkel M, Weber A and James Kirkpatrick C: Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorpholoic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 35:155–160. 2006. View Article : Google Scholar : PubMed/NCBI
10	Hoefert S, Wierich W, Eufinger H and Krempien B: BP-associated vascular necrosis (AN) of the jaws: histological findings. Bone. 38(suppl 1): 762006. View Article : Google Scholar
11	De Ceulaer J, Tacconelli E and Vandecasteele SJ: Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? Eur J Clin Microbiol Infect Dis. 33:1873–1880. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, Yatani H and Yoneda T: Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 28:165–175. 2010. View Article : Google Scholar
13	Berti-Couto SA, Vasconcelos AC, Iglesias JE, Figueiredo MA, Salum FG and Cherubini K: Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats. Head Neck. 36:84–93. 2014. View Article : Google Scholar
14	Molcho S, Peer A, Berg T, Futerman B and Khamaisi M: Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: A single center study. J Clin Endocrinol Metab. 98:E1807–E1812. 2013. View Article : Google Scholar : PubMed/NCBI
15	Nisi M, La Ferla F, Karapetsa D, Gennai S, Miccoli M, Baggiani A, Graziani F and Gabriele M: Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg. 44:586–591. 2015. View Article : Google Scholar : PubMed/NCBI
16	Valluru M, Staton CA, Reed MWR and Brown NJ: Transforming growth factor-β and endoglin signaling orchestrate wound healing. Front Physiol. 2:892011. View Article : Google Scholar
17	Tipton DA and Dabbous MK: Autocrine transforming growth factor β stimulation of extracellular matrix production by fibroblasts from fibrotic human gingiva. J Periodontol. 69:609–619. 1998. View Article : Google Scholar : PubMed/NCBI
18	Cotrim P, Martelli-Junior H, Graner E, Sauk JJ and Coletta RD: Cyclosporin A induces proliferation in human gingival fibroblasts via induction of transforming growth factor-beta1. J Periodontol. 74:1625–1633. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wu MY and Hill CS: TGF-β superfamily signaling in embryonic development and homeostasis. Dev Cell. 16:329–343. 2009. View Article : Google Scholar : PubMed/NCBI
20	Goumans MJ, Liu Z and ten Dijke P: TGF-β signaling in vascular biology and dysfunction. Cell Res. 19:116–127. 2009. View Article : Google Scholar
21	Heldin CH, Landström M and Moustakas A: Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol. 21:166–176. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu T and Feng XH: Regulation of TGF-β signalling by protein phosphatases. Biochem J. 430:191–198. 2010. View Article : Google Scholar : PubMed/NCBI
23	Meulmeester E and Ten Dijke P: The dynamic roles of TGF-β in cancer. J Pathol. 223:205–218. 2011. View Article : Google Scholar
24	Song B, Estrada KD and Lyons KM: Smad signaling in skeletal development and regeneration. Cytokine Growth Factor Rev. 20:379–388. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sandbo N and Dulin N: Actin cytoskeleton in myofibroblast differentiation: ultrastructure defining form and driving function. Transl Res. 158:181–196. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kimura H, Okubo N, Chosa N, Kyakumoto S, Kamo M, Miura H and Ishisaki A: EGF positively regulates the proliferation and migration, and negatively regulates the myofibroblast differentiation of periodontal ligament-derived endothelial progenitor cells through MEK/ERK- and JNK-dependent signals. Cell Physiol Biochem. 32:899–914. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sobral LM, Montan PF, Zecchin KG, Martelli-Junior H, Vargas PA, Graner E and Coletta RD: Smad7 blocks transforming growth factor-β1-induced gingival fibroblast-myofibroblast transition via inhibitory regulation of Smad2 and connective tissue growth factor. J Periodontol. 82:642–651. 2011. View Article : Google Scholar
28	Motizuki M, Isogaya K, Miyake K, Ikushima H, Kubota T, Miyazono K, Saitoh M and Miyazawa K: Oligodendrocyte transcription factor 1 (Olig1) is a Smad cofactor involved in cell motility induced by transforming growth factor-β. J Biol Chem. 288:18911–18922. 2013. View Article : Google Scholar : PubMed/NCBI
29	Nakano N, Maeyama K, Sakata N, Itoh F, Akatsu R, Nakata M, Katsu Y, Ikeno S, Togawa Y, Vo Nguyen TT, et al: C18 ORF1, a novel negative regulator of transforming growth factor-β signaling. J Biol Chem. 289:12680–12692. 2014. View Article : Google Scholar : PubMed/NCBI
30	Xiao Y-Q, Liu K, Shen J-F, Xu G-T and Ye W: SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol Vis Sci. 50:1698–1706. 2009. View Article : Google Scholar
31	Bakin AV, Rinehart C, Tomlinson AK and Arteaga CL: p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci. 115:3193–3206. 2002.PubMed/NCBI
32	Sarrazy V, Billet F, Micallef L, Coulomb B and Desmoulière A: Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen. 19(Suppl 1): s10–s15. 2011. View Article : Google Scholar : PubMed/NCBI
33	Van De Water L, Varney S and Tomasek JJ: Mechanoregulation of the myofibroblast in wound contraction, scarring, and fibrosis: Opportunities for new therapeutic intervention. Adv Wound Care (New Rochelle). 2:122–141. 2013. View Article : Google Scholar
34	Hinz B: Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 127:526–537. 2007. View Article : Google Scholar : PubMed/NCBI
35	Yoshinami T, Yagi T, Sakai D, Sugimoto N and Imamura F: A case of acquired Fanconi syndrome induced by zoledronic acid. Intern Med. 50:1075–1079. 2011. View Article : Google Scholar : PubMed/NCBI
36	Kurishima K, Ohara G, Kagohashi K, Takayashiki N, Tamura T, Shiozawa T, Miyazaki K, Kawaguchi M, Satoh H and Hizawa N: Ossification and increased bone mineral density with zoledronic acid in a patient with lung adenocarcinoma: a case report. Exp Ther Med. 8:1267–1270. 2014.PubMed/NCBI
37	DeMaio L, Buckley ST, Krishnaveni MS, Flodby P, Dubourd M, Banfalvi A, Xing Y, Ehrhardt C, Minoo P, Zhou B, et al: Ligand-independent transforming growth factor-β type I receptor signalling mediates type I collagen-induced epithelial-mesenchymal transition. J Pathol. 226:633–644. 2012. View Article : Google Scholar
38	Xu X, Wan X, Geng J, Li F, Wang C and Dai H: Kinase inhibitors fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue. Int J Mol Med. 32:430–438. 2013.PubMed/NCBI
39	Sawada S, Chosa N, Ishisaki A and Naruishi K: Enhancement of gingival inflammation induced by synergism of IL-1β and IL-6. Biomed Res. 34:31–40. 2013. View Article : Google Scholar : PubMed/NCBI
40	Wang X, Chu J, Wen CJ, Fu SB, Qian YL, Wo Y, Wang C and Wang DR: Functional characterization of TRAP1-like protein involved in modulating fibrotic processes mediated by TGF-β/Smad signaling in hypertrophic scar fibroblasts. Exp Cell Res. 332:202–211. 2015. View Article : Google Scholar : PubMed/NCBI
41	Lu Q: Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5. Am J Physiol Lung Cell Mol Physiol. 295:L123–L133. 2008. View Article : Google Scholar : PubMed/NCBI
42	Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ and Zannettino AC: The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone. 34:112–123. 2004. View Article : Google Scholar : PubMed/NCBI
43	Koch FP, Merkel C, Al-Nawas B, Smeets R, Ziebart T, Walter C and Wagner W: Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner - a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg. 39:562–569. 2011. View Article : Google Scholar
44	Chen YJ, Chao KS, Yang YC, Hsu ML, Lin CP and Chen YY: Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells. Immunopharmacol Immunotoxicol. 31:499–508. 2009. View Article : Google Scholar : PubMed/NCBI
45	Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B and Walter C: The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes - in vitro study. Clin Oral Investig. 16:87–93. 2012. View Article : Google Scholar
46	Tarnawski AS: Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci. 50(Suppl 1): S24–S33. 2005. View Article : Google Scholar : PubMed/NCBI
47	Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y and Wrana JL: Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 307:1603–1609. 2005. View Article : Google Scholar : PubMed/NCBI
48	Tojkander S, Gateva G and Lappalainen P: Actin stress fibers - assembly, dynamics and biological roles. J Cell Sci. 125:1855–1864. 2012. View Article : Google Scholar : PubMed/NCBI
49	Saito T, Izumi K, Shiomi A, Uenoyama A, Ohnuki H, Kato H, Terada M, Nozawa-Inoue K, Kawano Y, Takagi R and Maeda T: Zoledronic acid impairs re-epithelialization through down-regulation of integrin αvβ6 and transforming growth factor beta signalling in a three-dimensional in vitro wound healing model. Int J Oral Maxillofac Surg. 43:373–380. 2014. View Article : Google Scholar
50	Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, et al: Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Cell Death Dis. 5:e15172014. View Article : Google Scholar : PubMed/NCBI
51	Aloisi AL and Bucci C: Rab GTPases-cargo direct interactions: fine modulators of intracellular trafficking. Histol Histopathol. 28:839–849. 2013.PubMed/NCBI
52	Hu H, Milstein M, Bliss JM, Thai M, Malhotra G, Huynh LC and Colicelli J: Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration. Mol Cell Biol. 28:1573–1583. 2008. View Article : Google Scholar
53	Kardassis D, Murphy C, Fotsis T, Moustakas A and Stournaras C: Control of transforming growth factor β signal transduction by small GTPases. FEBS J. 276:2947–2965. 2009. View Article : Google Scholar : PubMed/NCBI
54	Short M, Nemenoff RA, Zawada WM, Stenmark KR and Das M: Hypoxia induces differentiation of pulmonary artery adventitial fibroblasts into myofibroblasts. Am J Physiol Cell Physiol. 286:C416–C425. 2004. View Article : Google Scholar